RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE
Press release of JSC "BAYER"
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Online Access: | https://www.rpcardio.online/jour/article/view/1543 |